Send to

Choose Destination
Infect Dis (Lond). 2015 Apr;47(4):203-8. doi: 10.3109/00365548.2014.984321. Epub 2015 Feb 4.

Increased concentrations of the soluble mannose receptor in serum from patients with pneumococcal bacteraemia, and prediction of survival.

Author information

From the Department of Clinical Biochemistry, Aarhus University Hospital.



The soluble mannose receptor (sMR) is a new serum marker of macrophage activation. The aim of the present study was to investigate sMR as a prognostic marker in patients with invasive pneumococcal disease (IPD), and compare it to other inflammatory biomarkers.


Samples from 128 patients with IPD were collected at the time of first positive blood culture and analysed using an in-house sMR assay. Clinical data were retrieved from patient files. The main outcome investigated was in-hospital mortality.


The median sMR concentration in the entire group of patients was 0.77 mg/L. There was a significant difference in sMR concentration between patients below (n = 92, sMR = 0.82 mg/L) or above (n = 36, sMR = 0.73 mg/L) the age of 75 (p < 0.001). In the entire group there was a significant difference in sMR concentrations between survivors (n = 107, sMR = 0.72 mg/L) and non-survivors (n = 21, sMR = 1.38 mg/L), but for patients 75 years or older this difference was not statistically significant. For prediction of survival sMR seemed most promising (area under the receiver operating characteristic curve (AUC) = 0.79) compared with sCD163 (AUC = 0.70) and CRP (AUC = 0.73). In patients 75 years or older the AUC was lower for all three markers (sMR = 0.56, sCD163 = 0.38, CRP = 0.66).


The results of this study designate sMR as a potential new biomarker in infectious disease. Additionally, it emphasizes the importance of research into macrophage malfunction in elderly patients.


CD163; CD206; Mannose receptor; bacteraemia; biomarker; sepsis

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center